US Patent Issued to Convalife (Shanghai) on Feb. 17 for "PI3K inhibitor for use in the therapy of b cell lymphoma" (British Inventor)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,551,487, issued on Feb. 17, was assigned to Convalife (Shanghai) Co. Ltd. (Shanghai).

"PI3K inhibitor for use in the therapy of b cell lymphoma" was invented by Penelope Ward (Oxfordshire, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a compound of formula (I), or its pharmaceutically acceptable salt. The compound, or its pharmaceutically acceptable salt, is useful as a PI3K inhibitor and therefore in therapy. In particular, the compound, or its pharmaceutically acceptable salt, has utility in the treatment of B cell lymphoma."

The patent was filed on July 1, 2020, under Application No. 17/612,709.

*For ...